ASAP Act

The ASAP Act would amend the Social Security Act to provide Medicare coverage for blood-based dementia screening tests that detect pre-symptomatic and early-stage Alzheimer’s disease or related dementias, effective January 1, 2028. The bill defines eligible tests as those cleared, classified, or approved by the FDA, including genomic sequencing blood tests and other equivalent blood-based analyses such as cell-free nucleic acid tests, multiplex panels, or protein expression tests, as determined appropriate by the Secretary of Health and Human Services. It also amends Medicare payment provisions to include these screening tests under Section 1833(h)(1)(A). The legislation affects Medicare…

No official summary is available here. This one was written by AI from the bill’s text.